Every 10-Q that Xencor, Inc. (XNCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XNCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XNCR filings page.
Xencor reported Q2 2026 revenue of $51.2 million, up from $43.6 million a year earlier, driven mainly by higher Ultomiris royalties from Alexion and a $10.0 million milestone from Zenas for the obexelimab BLA filing. Alexion-related royalty revenue rose to $37.3 million in the quarter.
Research and development expenses increased to $71.9 million, with continued investment across oncology and autoimmune programs, while general and administrative costs were $16.4 million. Net loss for Q2 narrowed to $21.7 million (‑$0.29 per share) from $30.8 million.
As of June 30, 2026, Xencor held $486.4 million in cash, cash equivalents, and marketable debt securities, versus $610.8 million at year-end 2025, and believes this will fund operations for at least 12 months. After quarter-end, Alexion agreed to pay an aggregate $105.0 million to resolve the Ultomiris U.S. royalty dispute, eliminating future U.S. royalties while preserving ex‑U.S. royalty rights.
Xencor reported a sharply wider loss for the quarter ended March 31, 2026 as collaboration revenues fell and investment values declined. Total revenue dropped to $4.5 million from $32.7 million, mainly because prior-year Incyte milestones did not repeat and Ultomiris royalties were reduced.
Net loss attributable to Xencor increased to $128.9 million, or $1.71 per share, from $48.4 million. The company recorded a $51.9 million unrealized loss on its equity stake in Zenas BioPharma and reversed $6.6 million of previously recorded Ultomiris U.S. royalty revenue after Alexion disputed further U.S. payments.
Research and development expenses rose to $64.7 million as Xencor advanced multiple oncology and autoimmune programs, while general and administrative costs were stable. Cash, cash equivalents and marketable debt securities totaled $541.8 million, and management believes this will fund operations into 2028.
Xencor reported Q3 results with revenue of $20,999 from collaborations, milestones and royalties, down the P&L to an operating loss of $47,519. A strong swing in other income, including $44,201 of gains on marketable equity securities, narrowed the quarter’s net loss to $6,027.
Year to date, revenue reached $97,339, aided by Incyte milestones of $12,500 and $25,000 triggered by U.S. regulatory events. Research and development expense was $54,367 in Q3, and the company recorded asset impairment charges of $1,565 tied to pausing certain programs. Liquidity comprised cash and cash equivalents of $28,291, marketable debt securities of $358,493 current and $247,158 long term, and marketable equity securities of $84,260. Liabilities related to prior royalty sales declined to $133,138 after $55,037 of payments to OMERS. Net cash used in operating activities was $83,406 for the nine months. Shares outstanding were 71,410,469 as of October 30, 2025. The at‑the‑market facility remained unused, and pre‑funded warrants from September 2024 remain exercisable.